We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Monoclonal Antibody Staining Improves Detection of Gastric Bacteria

By LabMedica International staff writers
Posted on 30 Jan 2011
Immunohistochemical staining of endoscopic gastric biopsies with specific antibodies identifies the pathogenic bacteria Helicobacter pylori in upper gastrointestinal diseases. More...


Tissue sections cut from paraffin blocks can be immunochemically stained with polyclonal or specific monoclonal antibodies and examined microscopically to determine the presence or absence of H. pylori.

A retrospective study, conducted by PLUS Diagnostics Laboratories, Union, NJ, USA), used archived material of 300 biopsies that previously had been demonstrated as H. pylori gastritis. The polyclonal antibody immunohistochemical method (NCL-HPp) were compared with slides stained with a Novocastra monoclonal antibody, clone UCL3R (MHP). A monoclonal slide and a polyclonal slide were each prepared with two sections from the same level, that were cut at four micrometer thickness, and immunohistochemical staining was performed on the Bond instrument (Leica Microsystems, Wetzlar, Germany), from whom both the monoclonal and polyclonal antibodies are available.

All study immunohistochemical stained tissue slides were reviewed microscopically by two gastrointestinal pathologists from PLUS Diagnostics with extensive experience in interpretation of immunohistochemical stains and H. pylori assessment. Each set of histological sections were scored, and the results recorded. Results were classified as either positive or negative for H. pylori. The definition of a positive result was the presence of any stained organisms resembling H. pylori bacteria. The definition of negative was the absence of any stained H. pylori-like bacteria.

The sensitivity of the two methods was comparable with 96.2% of the cases identified by the monoclonal antibody method and 98.5% identified by the polyclonal antibody method. The pathologists' evaluations showed that 75.6% of cases displayed high quality organism morphology with the MHP compared with only 34.4% using NCL-HPp, and that 95.8% of cases displayed high quality background staining MHP compared with 87.3% using NCL-HPp.

The authors concluded that the new H. pylori monoclonal ULC3R antibody reagent (MHP) when compared to the polyclonal antibody, NCL-HPp, shows improved quality of organism morphology clarity and reduced nonspecific background staining, whereas the sensitivity of the two methods was comparable. The study was published in January 2011, in LabMedicine.

Related Links:
Leica Microsystems
PLUS Diagnostics




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.